Cancers, Journal Year: 2024, Volume and Issue: 16(21), P. 3631 - 3631
Published: Oct. 28, 2024
Cisplatin became a first-line chemotherapy regimen for lung cancer in the mid-1980s, marking pivotal advance treatment [...]
Language: Английский
Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(14), P. 4189 - 4189
Published: July 18, 2024
The leading cause of cancer deaths worldwide is attributed to non-small cell lung (NSCLC), necessitating a continual focus on improving the diagnosis and treatment this disease. In review, latest breakthroughs emerging trends in managing NSCLC are highlighted. Major advancements diagnostic methods, including better imaging technologies utilization molecular biomarkers, discussed. These have greatly enhanced early detection personalized plans. Significant improvements patient outcomes been achieved by new targeted therapies immunotherapies, providing hope for individuals with advanced NSCLC. This review discusses persistent challenges accessing treatments their associated costs despite recent progress. Promising research into therapies, such as CAR-T therapy oncolytic viruses, which could further revolutionize treatment, also aims inform inspire continued efforts improve patients globally, offering comprehensive overview current state future possibilities.
Language: Английский
Citations
11
Seminars in Nuclear Medicine, Journal Year: 2025, Volume and Issue: unknown
Published: March 1, 2025
Language: Английский
Citations
1
Diseases, Journal Year: 2024, Volume and Issue: 12(5), P. 93 - 93
Published: May 6, 2024
Lung cancer, characterized by its heterogeneity, presents a significant challenge in therapeutic management, primarily due to the development of resistance conventional drugs. This is often compounded tumor’s ability reprogram metabolic pathways, survival strategy that enables cancer cells thrive adverse conditions. review article explores complex link between drug and reprogramming lung offering detailed analysis molecular mechanisms treatment strategies. It emphasizes interplay changes crucial for developing effective therapies. examines impact current treatments on pathways significance considering factors combat resistance. highlights different challenges alterations non-small-cell small-cell underlining need subtype-specific treatments. Key signaling including PI3K/AKT/mTOR, MAPK, AMPK, have been discussed their roles promoting changes, alongside regulatory networks involved. evaluates emerging targeting metabolism, such as inhibitors, dietary combination therapies, assessing potential challenges. concludes with insights into role precision medicine biomarkers crafting personalized treatments, advocating promising approach enhance efficacy overcome underscores ongoing advancements hurdles integrating considerations therapy
Language: Английский
Citations
5
European Journal of Medicinal Chemistry, Journal Year: 2025, Volume and Issue: 286, P. 117268 - 117268
Published: Jan. 13, 2025
Language: Английский
Citations
0
Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 16
Published: Feb. 25, 2025
Manzamine A (MA), a bioactive compound derived from the marine sponge Haliclona sp., shows considerable therapeutic potential, particularly in treatment of various cancer types. Extracted with acetone and purified through chromatography, MA exhibits bioavailability 20.6% when administered orally rats, underscoring its feasibility for use. This disrupts key cellular mechanisms essential progression, including microtubule dynamics DNA replication enzymes, demonstrating strong anti-proliferative effects against multiple cell lines while sparing normal cells. Additionally, network pharmacology molecular docking studies reveal MA's interactions important targets related to lung such as EGFR SRC, bolstering potential novel anti-lung agent. Pathway analyses further indicate that influences critical signaling pathways involved tumor growth metastasis. Given urgent need effective treatments drug-resistant cancers limited toxicity profile MA, exploration pharmacological benefits mechanism could pave way new strategies cancer.
Language: Английский
Citations
0
Seminars in Nuclear Medicine, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 1, 2025
Language: Английский
Citations
0
Biochemical and Biophysical Research Communications, Journal Year: 2025, Volume and Issue: unknown, P. 151880 - 151880
Published: April 1, 2025
Language: Английский
Citations
0
Ceramics International, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 1, 2024
Language: Английский
Citations
3
The Journal of Physical Chemistry Letters, Journal Year: 2024, Volume and Issue: 15(43), P. 10866 - 10872
Published: Oct. 23, 2024
Most of the traditional fluorescent molecules have advantages high fluorescence quantum yield, good stability, and excellent structural adjustability, but they exhibit characteristics quenching caused by aggregation, which restricts their application in aqueous solutions or solids. The luminescence properties photosensitive potential aggregation-induced emission (AIE) materials a condensed state made them widely concerned scientific research field, so it is very challenging to regulate transformation aggregation-caused (ACQ) fluorophores into AIE fluorophores. In this study, coumarin fluorophore was used as matrix. After conjugating triphenylamine group, triphenylphosphine cation linked through alkyl chain obtain molecular probe NCTPP with characteristic, water solubility, mitochondrial green light imaging, chemotherapy photodynamic therapy capabilities. As far we know, first time that photosensitivity imparted ACQ-AIE conversion method.
Language: Английский
Citations
3
Cancers, Journal Year: 2024, Volume and Issue: 16(21), P. 3631 - 3631
Published: Oct. 28, 2024
Cisplatin became a first-line chemotherapy regimen for lung cancer in the mid-1980s, marking pivotal advance treatment [...]
Language: Английский
Citations
0